Johnson Fistel Investigates Hims & Hers Regulatory Evasion and Investor Impact
1. Johnson Fistel is investigating Hims for possible securities law violations. 2. Novo Nordisk terminated collaboration over concerns with Hims’ medication practices. 3. Allegations include misuse of compounded medications containing unauthorized substances. 4. Increased scrutiny may impact Hims’ business practices and legal standing. 5. Investors may seek recovery for losses from alleged misrepresentations by Hims.